1,974 results match your criteria Nature Reviews Clinical Oncology[Journal]


Author Correction: Therapeutic implications of germline genetic findings in cancer.

Nat Rev Clin Oncol 2019 Apr 17. Epub 2019 Apr 17.

Cancer Division, Garvan Institute of Medical Research, Sydney, Australia.

The originally published article contained errors in the main text and in figure 1 in the reported number of patients with pathogenic or likely pathogenic germline variants. The originally reported numbers did not take into account the presence of more than one variant in an individual patient. This has been corrected in the HTML and PDF versions of the manuscript. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-019-0212-6
Publisher Site
http://dx.doi.org/10.1038/s41571-019-0212-6DOI Listing
April 2019
1 Read

Pembrolizumab improves OS across PD-L1 subgroups.

Authors:
Conor A Bradley

Nat Rev Clin Oncol 2019 Apr 16. Epub 2019 Apr 16.

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0213-5DOI Listing

Towards individualized therapy for metastatic renal cell carcinoma.

Nat Rev Clin Oncol 2019 Apr 16. Epub 2019 Apr 16.

Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Over the past decade, the treatment landscape for patients with metastatic renal cell carcinoma (RCC) has evolved dramatically. The therapeutic options available have expanded and now include immune-checkpoint inhibitors, novel targeted agents and combination strategies, and thus optimal patient selection and treatment sequencing are increasingly pertinent for optimizing clinical outcomes. A better understanding of the underlying biology of the tumour and its microenvironment continues to drive the inception of new diagnostic and therapeutic approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0209-1DOI Listing
April 2019
1 Read

Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Nat Rev Clin Oncol 2019 Apr 9. Epub 2019 Apr 9.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

Targeted therapy and immunotherapy have greatly improved the prognosis of patients with metastatic melanoma, but resistance to these therapeutic modalities limits the percentage of patients with long-lasting responses. Accumulating evidence indicates that a persisting subpopulation of melanoma cells contributes to resistance to targeted therapy or immunotherapy, even in patients who initially have a therapeutic response; however, the root mechanism of resistance remains elusive. To address this problem, we propose a new model, in which dynamic fluctuations of protein expression at the single-cell level and longitudinal reshaping of the cellular state at the cell-population level explain the whole process of therapeutic resistance development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0204-6DOI Listing
April 2019
2 Reads
14.180 Impact Factor

Fulvestrant enables better outcomes.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Apr 9. Epub 2019 Apr 9.

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0211-7DOI Listing

Ga-PSMA-11 PET enables accurate detection of recurrent disease.

Authors:
Conor A Bradley

Nat Rev Clin Oncol 2019 Apr 5. Epub 2019 Apr 5.

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0210-8DOI Listing
April 2019
1 Read

Reliable results from several DNA sources.

Authors:
Diana Romero

Nat Rev Clin Oncol 2019 Apr 4. Epub 2019 Apr 4.

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0208-2DOI Listing

Brain metastases respond to neratinib plus capecitabine.

Authors:
Conor A Bradley

Nat Rev Clin Oncol 2019 Apr 2. Epub 2019 Apr 2.

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0207-3DOI Listing
April 2019
1 Read

TMB is linked with prognosis.

Authors:
Diana Romero

Nat Rev Clin Oncol 2019 Apr 1. Epub 2019 Apr 1.

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0206-4DOI Listing

Immunoediting defines prognosis.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 May;16(5):271

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0205-5DOI Listing

Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.

Nat Rev Clin Oncol 2019 Mar 26. Epub 2019 Mar 26.

Department of Fundamental Oncology, University of Lausanne, Lausanne, Vaud, Switzerland.

The development of immunotherapies over the past decade has resulted in a paradigm shift in the treatment of cancer. However, the majority of patients do not benefit from immunotherapy, presumably owing to insufficient reprogramming of the immunosuppressive tumour microenvironment (TME) and thus limited reinvigoration of antitumour immunity. Various metabolic machineries and nutrient-sensing mechanisms orchestrate the behaviour of immune cells in response to nutrient availability in the TME. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0203-7DOI Listing
March 2019
4 Reads

From TAT 2019.

Authors:
David Killock

Nat Rev Clin Oncol 2019 May;16(5):273

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0201-9DOI Listing

bTMB is a promising predictive biomarker.

Authors:
David Killock

Nat Rev Clin Oncol 2019 Mar 15. Epub 2019 Mar 15.

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0202-8DOI Listing

Lymphadenectomy is not always required.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Mar 12. Epub 2019 Mar 12.

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0200-xDOI Listing

Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.

Nat Rev Clin Oncol 2019 Mar 12. Epub 2019 Mar 12.

Neuroimmunology Programme, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain.

Paraneoplastic neurological syndromes (PNSs) comprise a group of disorders that can affect any part of the nervous system in patients with cancer and frequently result from autoimmune responses triggered by the ectopic expression of neuronal proteins in cancer cells. These disorders are rare, although the introduction of immune-checkpoint inhibitors (ICIs) into cancer treatment algorithms has renewed interest in PNSs. ICIs are associated with a considerably increased incidence of immunological toxicities compared with traditional anticancer therapies, including neurological immune-related adverse effects (nirAEs) that can manifest as PNSs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0194-4DOI Listing
March 2019
2 Reads

Immunotherapy for glioblastoma: quo vadis?

Nat Rev Clin Oncol 2019 Mar 13. Epub 2019 Mar 13.

CHU Lille, Neuro-oncology, General and Stereotaxic Neurosurgery Service, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0195-3DOI Listing
March 2019
2 Reads

MAIA under the microscope - bringing trial design into focus.

Nat Rev Clin Oncol 2019 Mar 8. Epub 2019 Mar 8.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0198-0DOI Listing

PD-L1 positivity predicts response.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Mar 7. Epub 2019 Mar 7.

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0199-zDOI Listing

Emerging epigenetic-modulating therapies in lymphoma.

Nat Rev Clin Oncol 2019 Mar 5. Epub 2019 Mar 5.

Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Despite considerable advances in the treatment of lymphoma, the prognosis of patients with relapsed and/or refractory disease continues to be poor; thus, a continued need exists for the development of novel approaches and therapies. Epigenetic dysregulation might drive and/or promote tumorigenesis in various types of malignancies and is prevalent in both B cell and T cell lymphomas. Over the past decade, a large number of epigenetic-modifying agents have been developed and introduced into the clinical management of patients with haematological malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0190-8DOI Listing
March 2019
1 Read

Healthier bones and less recurrence with denosumab.

Authors:
Diana Romero

Nat Rev Clin Oncol 2019 May;16(5):272

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0197-1DOI Listing
May 2019
2 Reads

Early responses indicate remission.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 May;16(5):272

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0196-2DOI Listing
May 2019
4 Reads

Mechanisms of resistance to CAR T cell therapy.

Nat Rev Clin Oncol 2019 Mar 5. Epub 2019 Mar 5.

Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas have revolutionized anticancer therapy, providing a potentially curative option for patients who are refractory to standard treatments. These trials resulted in rapid FDA approvals of anti-CD19 CAR T cell products for both ALL and certain types of B cell lymphoma - the first approved gene therapies in the USA. However, growing experience with these agents has revealed that remissions will be brief in a substantial number of patients owing to poor CAR T cell persistence and/or cancer cell resistance resulting from antigen loss or modulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0184-6DOI Listing
March 2019
6 Reads

Axitinib-ICIs boost the RCC armamentarium.

Authors:
Diana Romero

Nat Rev Clin Oncol 2019 Apr;16(4):207

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0193-5DOI Listing
April 2019
1 Read

The NKG2A immune checkpoint - a new direction in cancer immunotherapy.

Nat Rev Clin Oncol 2019 May;16(5):277-278

Thoracic Oncology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0182-8DOI Listing

Vessel co-option in cancer.

Nat Rev Clin Oncol 2019 Feb 28. Epub 2019 Feb 28.

Tumour Biology Team, Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.

All solid tumours require a vascular supply in order to progress. Although the ability to induce angiogenesis (new blood vessel growth) has long been regarded as essential to this purpose, thus far, anti-angiogenic therapies have shown only modest efficacy in patients. Importantly, overshadowed by the literature on tumour angiogenesis is a long-standing, but continually emerging, body of research indicating that tumours can grow instead by hijacking pre-existing blood vessels of the surrounding nonmalignant tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0181-9DOI Listing
February 2019
3 Reads

Anti-CD19 CAR T cell therapy for lymphoma - off to the races!

Authors:
David G Maloney

Nat Rev Clin Oncol 2019 May;16(5):279-280

Bezos Family Immunotherapy Clinic, Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0183-7DOI Listing
May 2019
1 Read

Time for a change and to adopt a novel molecular genomic approach in NETs.

Nat Rev Clin Oncol 2019 Apr;16(4):269-270

Department of Surgery, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0185-5DOI Listing

Reply to 'Time for a change and to adopt a novel molecular genomic approach in NETs'.

Nat Rev Clin Oncol 2019 Apr;16(4):270

Charité, Campus Virchow Klinikum and Charité Mitte, University Medicine Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0186-4DOI Listing
April 2019
2 Reads

Lomustine-temozolomide combination efficacious in newly diagnosed glioblastoma.

Authors:
David Killock

Nat Rev Clin Oncol 2019 May;16(5):273

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0192-6DOI Listing
May 2019
1 Read

ARAMIS - is darolutamide set to become the 'third musketeer' of nmCRPC?

Authors:
David Killock

Nat Rev Clin Oncol 2019 May;16(5):273

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0191-7DOI Listing
May 2019
1 Read

Liquid biopsy and minimal residual disease - latest advances and implications for cure.

Nat Rev Clin Oncol 2019 Feb 22. Epub 2019 Feb 22.

Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre and University of Montpellier, Montpellier, France.

Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free tumour DNA (ctDNA). Highly sensitive liquid biopsy assays have been developed that can now be applied to detect and characterize minimal residual disease (MRD), which reflects the presence of tumour cells disseminated from the primary lesion to distant organs in patients who lack any clinical or radiological signs of metastasis or residual tumour cells left behind after local therapy that eventually lead to local recurrence. This application is the new frontier of liquid biopsy analyses, which are challenged by the very low concentrations of CTCs and ctDNA in blood samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0187-3DOI Listing
February 2019
14.180 Impact Factor

Early PET response predicts complete response.

Authors:
Peter Sidaway

Nat Rev Clin Oncol 2019 Apr;16(4):208

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0189-1DOI Listing

CTCs 'piggyback' off neutrophils.

Authors:
David Killock

Nat Rev Clin Oncol 2019 Apr;16(4):208

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0188-2DOI Listing
April 2019
2 Reads

Therapeutic implications of germline genetic findings in cancer.

Nat Rev Clin Oncol 2019 Feb 19. Epub 2019 Feb 19.

Cancer Division, Garvan Institute of Medical Research, Sydney, Australia.

Cancer is a genetic disease. To date, translational cancer genomics has focused largely on somatic alterations, driven by the desire to identify targets for personalized therapy. However, therapeutically relevant information is also latent within the germline genome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0179-3DOI Listing
February 2019

Registration studies - when should patients be deemed ineligible for aggressive therapy?

Nat Rev Clin Oncol 2019 Feb 18. Epub 2019 Feb 18.

Division of Hematology Oncology, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0180-xDOI Listing
February 2019

Challenges to curing primary brain tumours.

Nat Rev Clin Oncol 2019 Feb 7. Epub 2019 Feb 7.

CRUK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK.

Despite decades of research, brain tumours remain among the deadliest of all forms of cancer. The ability of these tumours to resist almost all conventional and novel treatments relates, in part, to the unique cell-intrinsic and microenvironmental properties of neural tissues. In an attempt to encourage progress in our understanding and ability to successfully treat patients with brain tumours, Cancer Research UK convened an international panel of clinicians and laboratory-based scientists to identify challenges that must be overcome if we are to cure all patients with a brain tumour. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-019-0177-5
Publisher Site
http://dx.doi.org/10.1038/s41571-019-0177-5DOI Listing
February 2019
20 Reads

CSF DNA provides a snapshot of the glioma genome.

Authors:
David Killock

Nat Rev Clin Oncol 2019 Mar;16(3):143

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0178-4DOI Listing

The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches.

Nat Rev Clin Oncol 2019 Feb 4. Epub 2019 Feb 4.

Institute of Clinical Radiology, University Hospital Muenster, Muenster, Germany.

Owing to improvements in our understanding of the biological principles of tumour initiation and progression, a wide variety of novel targeted therapies have been developed. Developments in biomedical imaging, however, have not kept pace with these improvements and are still mainly designed to determine lesion size alone, which is reflected in the Response Evaluation Criteria in Solid Tumors (RECIST). Imaging approaches currently used for the evaluation of treatment responses in patients with solid tumours, therefore, often fail to detect successful responses to novel targeted agents and might even falsely suggest disease progression, a scenario known as pseudoprogression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0169-5DOI Listing
February 2019

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.

Nat Rev Clin Oncol 2019 Feb 4. Epub 2019 Feb 4.

Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, UK.

The era of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC) began when biomarker-based evidence of molecular pathway and/or oncogene addiction of the tumour became mandatory for the allocation of specific targeted therapies. More recently, the immunotherapy revolution, specifically, the development of immune-checkpoint inhibitors (ICIs), has dramatically altered the NSCLC treatment landscape. Herein, we compare and contrast the clinical development of immunotherapy and oncogene-directed therapy for NSCLC, focusing on the role of predictive biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0173-9DOI Listing
February 2019
5 Reads

Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.

Nat Rev Clin Oncol 2019 Jan 31. Epub 2019 Jan 31.

Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Centre (EPOC), National Cancer Centre, Tokyo/Chiba, Japan.

Regulatory T (T) cells, an immunosuppressive subset of CD4 T cells characterized by the expression of the master transcription factor forkhead box protein P3 (FOXP3), are a component of the immune system with essential roles in maintaining self-tolerance. In addition, T cells can suppress anticancer immunity, thereby hindering protective immunosurveillance of neoplasia and hampering effective antitumour immune responses in tumour-bearing hosts, thus promoting tumour development and progression. Identification of the factors that are specifically expressed in T cells and/or that influence T cell homeostasis and function is important to understanding cancer pathogenesis and to identifying therapeutic targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0175-7DOI Listing
January 2019

Real-world data: towards achieving the achievable in cancer care.

Nat Rev Clin Oncol 2019 May;16(5):312-325

Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada.

The use of data from the real world to address clinical and policy-relevant questions that cannot be answered using data from clinical trials is garnering increased interest. Indeed, data from cancer registries and linked treatment records can provide unique insights into patients, treatments and outcomes in routine oncology practice. In this Review, we explore the quality of real-world data (RWD), provide a framework for the use of RWD and draw attention to the methodological pitfalls inherent to using RWD in studies of comparative effectiveness. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-019-0167-7
Publisher Site
http://dx.doi.org/10.1038/s41571-019-0167-7DOI Listing
May 2019
2 Reads

Hybrid minimally invasive surgery overtakes open surgery.

Authors:
Diana Romero

Nat Rev Clin Oncol 2019 Mar;16(3):144

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0176-6DOI Listing

Rectal cancer - not a waiting game?

Authors:
David Killock

Nat Rev Clin Oncol 2019 Apr;16(4):209

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0174-8DOI Listing
April 2019
1 Read

Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review.

Nat Rev Clin Oncol 2019 Mar;16(3):139-141

Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0170-zDOI Listing

CRISPR-Cas: a tool for cancer research and therapeutics.

Nat Rev Clin Oncol 2019 May;16(5):281-295

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.

In the past decade, the development of a genome-editing technology mediated by CRISPR has made genetic engineering easier than ever, both in vitro and in vivo. CRISPR systems have enabled important advances in cancer research by accelerating the development of study models or as a tool in genetic screening studies, including those aiming to discover and validate therapeutic targets. In this Review, we discuss these applications as well as new potential uses of CRISPR to assist in cancer detection or the development of anticancer therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0166-8DOI Listing
May 2019
1 Read

Desmoid tumours stalled by sorafenib.

Nat Rev Clin Oncol 2019 Apr;16(4):209

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0172-xDOI Listing

FOLFIRINOX goes adjuvant.

Authors:
Diana Romero

Nat Rev Clin Oncol 2019 Mar;16(3):145

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0171-yDOI Listing
March 2019
2 Reads

Towards risk-stratified induction regimens.

Authors:
David Killock

Nat Rev Clin Oncol 2019 Apr;16(4):209

Nature Reviews Clinical Oncology, .

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-019-0168-6
Publisher Site
http://dx.doi.org/10.1038/s41571-019-0168-6DOI Listing
April 2019
9 Reads

Truly personalized therapy - an end to the era of one size fits all.

Nat Rev Clin Oncol 2019 Feb;16(2):77-78

Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center (CCCLMU), University of Munich (LMU), Munich, Germany.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0165-1
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0165-1DOI Listing
February 2019
13 Reads

Reshaping the critical role of surgeons in oncology research.

Nat Rev Clin Oncol 2019 May;16(5):327-332

North Western Hepatobiliary Unit, Aintree University Hospital, Liverpool, UK.

Surgery remains a mainstay in the treatment of most solid cancers. Surgeons have always engaged in various forms of high-quality cancer research to optimize outcomes for their patients, for example, contributing to clinical research and outcomes research as well as health education and public health policy. Over the past decade, however, concerns have been raised about a global decline in the number of surgeons performing basic science research alongside clinical activity - so-called surgeon scientists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0149-1DOI Listing
May 2019
13 Reads